4T1 Syngeneic Model Overview
The 4T1 syngeneic model is an extensively validated murine system for the study of triple-negative breast cancer (TNBC) in an immunocompetent environment. Derived from a spontaneous mammary tumor in a BALB/c mouse, the 4T1 cell line exhibits a highly aggressive and metastatic phenotype that closely parallels human TNBC in both growth kinetics and disease progression. When implanted orthotopically into the mammary fat pad of BALB/c mice, the model produces rapidly growing tumors that spontaneously metastasize to the lungs, liver, brain, and bone, reflecting the multi-organ dissemination observed in patients with advanced disease.
The 4T1 model preserves the complete functionality of the host immune system, allowing detailed evaluation of tumor-immune interactions, immune evasion mechanisms, and therapeutic modulation of the tumor microenvironment. Its reproducible growth pattern, short latency period, and predictable metastatic behavior make it a preferred platform for immuno-oncology research, including studies involving checkpoint blockade, adoptive cell therapy, cytokine modulation, and combination regimens designed to overcome immune suppression.
Request a Custom Quote for 4T1 Syngeneic ModelBiological and Molecular Characteristics
The 4T1 cell line was established from a spontaneous mammary carcinoma of BALB/c origin and displays epithelial morphology consistent with a basal-like TNBC phenotype. It lacks expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, classifying it as triple-negative. The tumors express high levels of vimentin, CXCL1, CXCL2, and vascular endothelial growth factor (VEGF), which contribute to angiogenesis, invasion, and metastatic dissemination. The microenvironment is enriched with myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages, and regulatory T cells, resulting in a profoundly immunosuppressive phenotype that mirrors the tumor-immune balance of human breast cancer.
| Parameter | Description |
|---|---|
| Host strain | BALB/c (female, 6–8 weeks) |
| Tumor origin | Spontaneous mammary carcinoma (mouse) |
| Receptor status | ER– / PR– / HER2– |
| Inoculation route | Orthotopic (mammary fat pad) or subcutaneous |
| Tumor take rate | >95% |
| Doubling time | Approximately 2.5–3.5 days in vivo |
| Metastatic sites | Lungs, liver, bone, brain |
| Immunophenotype | High myeloid infiltration, limited CD8⁺ T-cell activity |
| Common applications | Immunotherapy, checkpoint blockade, combination therapy |
In Vivo Model Development and Tumorigenicity
Tumors are established through orthotopic implantation of 4T1 cells into the mammary fat pad of BALB/c mice. Palpable nodules typically appear within one week of implantation, progressing rapidly thereafter. This model demonstrates a consistent tumor take rate and spontaneous metastasis to distant organs within three to four weeks, enabling comprehensive evaluation of both primary and systemic disease. Subcutaneous inoculation may also be used when localized tumor growth and external monitoring are desired.
Because the 4T1 model maintains an intact immune system, it provides a realistic environment for analyzing immune infiltration, cytokine dynamics, and the interplay between tumor progression and host immunity. The aggressive nature of tumor growth allows for short, well-controlled study durations, facilitating efficient testing of therapeutic agents targeting either immune checkpoints or components of the tumor stroma.
Request a Custom Quote for 4T1 Syngeneic ModelHistopathology and Immunohistochemical Profile
Histologically, 4T1 tumors display solid epithelial nests surrounded by dense fibrovascular stroma, with high mitotic activity and areas of necrosis. Prominent vascularization supports rapid tumor expansion and facilitates metastatic dissemination. The tumor parenchyma is heavily infiltrated by macrophages and granulocytes, while lymphocytic infiltration remains sparse, producing an immunologically “cold” profile that parallels advanced TNBC in humans.
Immunohistochemical evaluation demonstrates strong Ki-67 expression, indicative of rapid proliferation, along with moderate to high PD-L1 expression on tumor and immune cells. Staining for F4/80 and Gr-1 confirms abundant myeloid and suppressor cell populations, whereas CD3 and CD8 staining reveal limited cytotoxic lymphocyte presence. This composition of cellular elements defines the immunosuppressive landscape that underlies the 4T1 model’s therapeutic relevance and its resistance to single-agent immune checkpoint therapy.
Preclinical Applications and Drug Response
The 4T1 syngeneic model is an essential system for evaluating novel immuno-oncology strategies targeting TNBC. It supports a broad range of studies, including immune checkpoint blockade using PD-1, PD-L1, and CTLA-4 inhibitors; adoptive T-cell and dendritic-cell-based immunotherapy; cytokine or mRNA delivery approaches; and oncolytic viral therapy. The model’s aggressive progression and metastatic potential allow researchers to assess both local tumor control and systemic immune activation following therapeutic intervention.
Combination therapy studies are particularly informative in this model, where co-administration of checkpoint inhibitors with chemotherapy, radiation, or cytokine modulators can produce synergistic effects. The 4T1 system remains one of the most reliable murine models for dissecting the molecular and immunological determinants of therapeutic response and resistance in triple-negative breast cancer, serving as a critical translational bridge between discovery research and clinical immunotherapy development.
Request This Model
To request the 4T1 syngeneic model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for 4T1 Syngeneic Model